1412418-47-3

Basic information

• Product Name: Btk inhibitor 1
• Synonyms: Btk inhibitor 1
• CAS NO: 1412418-47-3
• Molecular Formula: C₂₂H₂₂N₆O
• Molecular Weight: 386.44968
• Mol File: 1412418-47-3.mol
• Article Data: 7

Chemical Properties

• Boiling Point: 626.3±55.0 °C(Predicted)
• Appearance: /
• Density: 1.39±0.1 g/cm3(Predicted)
• PKA: 9.00±0.10(Predicted)
• CAS DataBase Reference: Btk inhibitor 1(CAS DataBase Reference)
• NIST Chemistry Reference: Btk inhibitor 1(1412418-47-3)
• EPA Substance Registry System: Btk inhibitor 1(1412418-47-3)

Safety Data

• Hazardous Substances Data: 1412418-47-3(Hazardous Substances Data)

Usage

General Description

Btk inhibitor 1 is a chemical compound that acts as an inhibitor of Bruton’s tyrosine kinase (Btk), a protein involved in the regulation of B cell development and function. This chemical works by binding to Btk and blocking its activity, leading to a suppression of B cell activation and proliferation. This makes Btk inhibitor 1 a potential therapeutic agent for the treatment of B cell-related diseases, such as leukemia and autoimmune disorders. Its ability to specifically target Btk and modulate B cell signaling pathways makes it a promising candidate for the development of new drugs targeting B cell-mediated diseases.

Upstream product

• 144243-24-3 tert‐butyl 3‐aminopiperidine‐1‐carboxylate 
• 5305-45-3 4,6-dichloro-5-cyanopyrimidine 
• 19300-54-0 toluene-4-sulfonic acid pent-4-enyl ester 
• 1609467-43-7 benzyl 3-[5-amino-4-cyano-3-(4-phenoxy-phenyl)-pyrazol-1-yl]-piperidine-1-carboxylate 
• 330792-68-2 2-[hydroxy-(4-phenoxy-phenyl)-methylene]-malononitrile 
• 1623-95-6 4-phenoxybenzoyl chloride 
• 2215-77-2 4-Phenoxybenzoic acid 
• 940890-90-4 (S)-3-methanesulfonyloxy-piperidine-1-carboxylic acid tert-butyl ester 
• 51067-38-0 4-phenoxyphenylboronic acid 
• 85275-45-2 N-tert-butoxycarbonyl-3-piperidinol 
• 330786-24-8 3-(4-phenoxyphenyl)-1H-pyrazolo[3,4-d]pyrimidin-4-amine 
• 129888-60-4 1-(tert-Butoxycarbonyl)-3-(methanesulfonyloxy)piperidine 
• 1276110-38-3 (R)-3-(4-amino-3-iodo-1H-pyrazolo[3,4-d]pyrimidin-1-yl)piperidine-1-carboxylic acid tert-butyl ester 
• 98977-36-7 3-oxo-piperidine-1-carboxylic acid tert-butyl ester 

Downstream Products

• 1412418-06-4 3-(3-(4-amino-3-(4-phenoxyphenyl)-1H-pyrazolo[3,4-d]pyrimidin-1-yl)piperidin-1-yl)-3-oxopropanenitrile 
• 1412418-65-5 _{(R)-2-(3-(4-amino-3-(4-phenoxyphenyl)-1H-pyrazolo[3,4-d]pyrimidin-1-yl)piperidine-1-carbonyl)-4,4-dimethylpent-2-enenitrile} 
• 1412418-18-8 (R)-2-(3-(4-amino-3-(4-phenoxyphenyl)-1H-pyrazolo[3,4-d]pyrimidin-1-yl)piperidine-1-carbonyl)-3-cyclopropylacrylonitrile 
• 1412418-48-4 (2E)-2-[(E)-[(3R)-3-[4-amino-3-(4-phenoxyphenyl)-1H-pyrazolo[3,4-d]pyrimidin-1-yl]piperidin-1-yl]carbonyl]-3-cyclopropylprop-2-enenitrile 
• 1412418-08-6 2-(3-(4-amino-3-(4-phenoxyphenyl)-1H-pyrazolo[3,4-d]pyrimidin-1-yl)piperidine-1-carbonyl)-4,4-dimethylpent-2-enenitrile 
• 936563-87-0 ibrutinib 
• 936563-87-0 1-[(3R)-3-[4-amino-3-(4-phenoxyphenyl)pyrazolo[3,4-d]pyrimidin-1-yl]piperidin-1-yl]prop-2-en-1-one 

Relevant articles and documents

BENZENESULFONAMIDE DERIVATIVES AND USES THEREOF

Provided herein are benzenesulfonamide derivatives having Formula (III), pharmaceutical compositions comprising said compounds, and method for using said compounds for disrupting proteins/polypeptides, protein/polypeptide function, and for the treatment of diseases through the disruption of proteins or polypeptides involved in the etiology of the disease. Said compounds comprise fluorinated benzene sulfonamide structures.

Catalytic Azido-Hydrazination of Alkenes Enabled by Visible Light: Mechanistic Studies and Synthetic Applications

A visible-light-enabled catalytic intermolecular azido-hydrazination method for unactivated alkenes is developed via an orderly radical addition sequence. This transformation features metal-free and redox-neutral conditions and is applicable to a wide range of alkenes with commercially available reagents. Mechanistic and kinetic studies reveal that the efficient generation of azide radical enabled by fluorenone under visible-light is critical to this methodology. The β-azido alkyl hydrazines prepared with this reaction can be conveniently derived to valuable synthetic building blocks, and one of the products has been successfully applied in the total synthesis of (±)-ibrutinib, which is used to treat B cell cancers. (Figure presented.).

KINASE INHIBITORS

Provided herein are kinase inhibiting compounds and methods of using the same.